US grant · National Institutes of Health
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
Up to $700,000 Closes January 11, 2027
Official listing and how to apply
Source: Grants.gov · Last checked
Key facts
| Funder | National Institutes of Health |
|---|---|
| Part of | Department of Health and Human Services |
| Opportunity number | RFA-CA-27-005 |
| Amount per award | Up to $700,000 |
| Total funding available | $4,400,000 |
| Opens | August 31, 2026 |
| Closes | January 11, 2027 (62 days left) |
| Who can apply | Schools and universities, Businesses, Government, Nonprofits, Other (see listing), Tribal organizations |
| Applicant types listed | Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Public housing authorities/Indian housing authorities; Special district governments; Native American tribal governments (Federally recognized); State governments; Small businesses; Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education; Independent school districts; For profit organizations other than small businesses |
| State or area | Nationwide |
| Cost sharing or match | Not required |
| Status | Open |
| Source | Grants.gov |
| Last checked | November 10, 2026 |
About this grant
Summary from the official listing on Grants.gov:
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.
To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Details are copied from the official source and can change. Check the official listing before you apply. Grant Writing Company is not affiliated with this funder.
Want an expert to write it with you?
Grant Writing Company researches funders, writes organization proposals to each funder's instructions, and checks the package before you submit. experience since 2006. Funders decide every award.